Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders

Neuroscience and Biobehavioral Reviews

Volumn 32, Issue 6, 2008, Pages 1152-1160

  Gorzalka, Boris B ^a   Hill, Matthew N ^a   Hillard, Cecilia J ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

2 AG; Adaptation; Anandamide; Antidepressant; Cannabinoid; Depression; FAAH; Habituation; Hypothalamus; Prefrontal cortex; Stress

Indexed keywords

CORTICOSTERONE; DEXAMETHASONE; ENDOCANNABINOID;

ACUTE STRESS; AVERSIVE BEHAVIOR; CHRONIC STRESS; DEPRESSION; HABITUATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MENTAL STRESS; MOOD DISORDER; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ENDOCANNABINOIDS; HUMANS; MOOD DISORDERS; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

EID: 45849113264     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2008.03.004     Document Type: Review

References (105)

1. Aguado T., Monory K., Palazuelos J., Stella N., Cravatt B., Lutz B., Marsicano G., Kokaia Z., Guzman M., and Galve-Roperh I. The endocannabinoid system drives neural progenitor proliferation. FASEB J. 19 (2005) 1704-1706
2. Alfarez D.N., Joels M., and Kruger H.J. Chronic unpredictable stress impairs long-term potentiation in rat hippocampal CA1 area and dentate gyrus in vitro. Eur. J. Neurosci. 17 (2003) 1928-1934
3. Armario A. The hypothalamic-pituitary-adrenal axis: what can it tell us about stressors?. CNS Neurol. Disord. Drug Targets 5 (2006) 485-501
4. Barna I., Zelena D., Arszovszki A.C., and Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci. 75 (2004) 2959-2970
5. Basavarajappa B.S. Critical enzymes involved in endocannabinoid metabolism. Protein Pept. Lett. 14 (2007) 237-246
6. Bisogno T., Ligresti A., and Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol. Biochem. Behav. 81 (2005) 224-238
7. Bisogno T., Melck D., Bobrov M.Y., Gretskaya N.M., Bezuglov V.V., De Petrocellis L., and Di Marzo V. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 351 (2000) 817-824
8. Bortolato M., Mangieri R.A., Fu J., Kim J.H., Arguello O., Duranti, Tontini A., Mor M., Tarzia G., and Piomelli D. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol. Psychiatry 62 (2007) 1103-1110
9. Brilman E.I., and Ormel J. Life events, difficulties and onset of depressive episodes in later life. Psychol. Med. 31 (2001) 859-869
10. Cabral G.A., and Marciano-Cabral F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J. Leukoc. Biol. 78 (2005) 1192-1197
11. Carrier E.J., Kearn C.S., Barkmeier A.J., Breese N.M., Yang W., Nithipatikom K., Pfister S.L., Campbell W.B., and Hillard C.J. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol. Pharmacol. 65 (2004) 999-1007
12. Connor T.J., Kelliher P., Shen Y., Harkin A., Kelly J.P., and Leonard B.E. Effect of subchronic antidepressant treatments on behavioral, neurochemical, and endocrine changes in the forced-swim test. Pharmacol. Biochem. Behav. 65 (2000) 591-597
13. Cota D., Steiner M.A., Marsicano G., Cervino C., Herman J.P., Grubler Y., Stalla J., Pasquali R., Lutz B., Stalla G.K., and Pagotto U. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 148 (2007) 1574-1581
14. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., and Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 9371-9376
15. Dallman M.F., Akana S.F., Levin N., Walker C.D., Bradbury M.J., Suemaru S., and Scribner K.S. Corticosteroids and the control of function in the hypothalamo-pituitary-adrenal (HPA) axis. Ann. N.Y. Acad. Sci. 746 (1994) 22-31
16. de Medeiros M.A., Carlos Reis L., and Eugenio Mello L. Stress-induced c-Fos expression is differentially modulated by dexamethasone, diazepam and imipramine. Neuropsychopharmacology 30 (2005) 1246-1256
17. Deutsch D.G., Ueda N., and Yamamoto S. The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot. Essent. Fatty Acids 66 (2002) 201-210
18. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
19. Di S., Malcher-Lopes R., Halmos K.C., and Tasker J.G. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J. Neurosci. 23 (2003) 4850-4857
20. Di S., Malcher-Lopes R., Marcheselli V.L., Bazan N.G., and Taskr J.G. Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 146 (2005) 4292-4301
21. Di Marzo V., De Petrocellis L., Sepe N., and Buono A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J. 316 (1996) 977-984
22. Di Marzo V., Melck D., Bisogno T., and De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21 (1998) 521-528
23. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., and Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 10819-10824
24. Duncan G.E., Knapp D.J., Carson S.W., and Breese G.R. Functional classification of antidepressants based on antagonism of swim stress-induced fos-like immunoreactivity. J. Pharmacol. Exp. Ther. 277 (1996) 1076-1089
25. Felder C.C., and Glass M. Cannabinoid receptors and their endogenous agonists. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 179-200
26. Freund T.F., Katona I., and Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83 (2003) 1017-1066
27. Fride E., Suris R., Weidenfeld J., and Mechoulam R. Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice. Behav. Pharmacol. 16 (2005) 431-440
28. Gardner E.L. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol. Biochem. Behav. 81 (2005) 263-284
29. 1 receptor blockade rapidly enhances the hormonal response to restraint. Soc. Neurosci. Abstr. 563 (2006) 8
30. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., Cassano T., Morgese M.G., Debonnel G., Duranti A., Tontini A., Tarzia G., Mor M., Trezza V., Goldberg S.R., Cuomo V., and Piomelli D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 18620-18625
31. Gong J.P., Onaivi E.S., Ishiguro H., Liu Q.R., Tagliaferro P.A., Brusco A., and Uhl G.R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071 (2006) 10-23
32. Gorzalka B.B., and Hill M.N. Cannabinoids, reproduction and sexual behavior. Annu. Rev. Sex. Res. 17 (2006) 132-161
33. Haller J., Varga B., Ledent C., Barna I., and Freund T.F. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur. J. Neurosci. 19 (2004) 1906-1912
34. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanoivch I., and Mechoulam R. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 3662-3665
35. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11 (1991) 563-583
36. Herman J.P., Adams D., and Prewitt C. Regulatory changes in neuroendocrine stress-integrative circuitry produced by a variable stress paradigm. Neuroendocrinology 61 (1995) 180-190
37. Herman J.P., Figueiredo H., Mueller N.K., Ulrich-Lai Y., Ostrander M.M., Choi D.C., and Cullinan W.E. Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front. Neuroendocrinol. 24 (2003) 151-180
38. Herman J.P., Tasker J.G., Ziegler D.R., and Cullinan W.E. Local circuit regulation of paraventricular nucleus stress integration: glutamate-GABA connections. Pharmacol. Biochem. Behav. 71 (2002) 457-468
39. Hill M.N., Carrier E.J., Ho W.S., Shi L., Patel S., Gorzalka B.B., and Hillard C.J. Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor binding in the hippocampus. Hippocampus 18 (2008) 221-226
40. Hill M.N., and Gorzalka B.B. Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. Eur. J. Pharmacol. 499 (2004) 291-295
41. Hill M.N., and Gorzalka B.B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur. Neuropsychopharmacol. 15 (2005) 593-599
42. Hill M.N., and Gorzalka B.B. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behav. Pharmacol. 16 (2005) 333-352
43. Hill M.N., Ho W.S., Meier S.E., Gorzalka B.B., and Hillard C.J. Chronic corticosterone treatment increases the endocannabinoid 2-arachidonylglycerol in the rat amygdala. Eur. J. Pharmacol. 528 (2005) 99-102
44. Hill M.N., Ho W.S., Sinopoli K.J., Viau V., Hillard C.J., and Gorzalka B.B. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 31 (2006) 2591-2599
45. Hill M.N., Kambo J.S., Sun J.C., Gorzalka B.B., and Galea L.A. Endocannabinoids modulate stress-induced suppression of hippocampal cell proliferation and activation of defensive behaviours. Eur. J. Neurosci. 24 (2006) 1845-1849
46. Hill M.N., Karacabeyli E.S., and Gorzalka B.B. Estrogen recruits the endocannabinoid system to modulate emotionality. Psychoneuroendocrinology 32 (2007) 350-357
47. Hill M.N., Miller G.E., Carrier E.J., Ho W.S., Gorzalka B.B., and Hillard C.J. Dynamic regulation of serum endocannabinoid content following exposure to social stress in humans and in affective disease. 16th Annu. Symp. Int. Cannabinoid Res. Soc. (2006) 67
48. Hill M.N., Miller G.E., Ho W.S., Gorzalka B.B., and Hillard C.J. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 41 (2008) 48-53
49. Hill M.N., Patel S., Carrier E.J., Rademacher D.J., Ormerod B.K., Hillard C.J., and Gorzalka B.B. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30 (2005) 508-515
50. Hillard C.J. Endocannabinoids and vascular function. J. Pharmacol. Exp. Ther. 294 (2000) 27-32
51. Hillard C.J., Hill M.N., Carrier E.J., Shi L., Cullinan W.E., and Gorzalka B.B. Regulation of cannabinoid receptor expression by chronic, unpredictable stress in rats and mice. Soc. Neurosci. Abstr. 746. (2006) 19
52. Hillard C.J., and Jarrahian A. Cellular accumulation of anandamide: consensus and controversy. Br. J. Pharmacol. 140 (2003) 802-808
53. Hohmann A.G., Suplita R.L., Bolton N.M., Neely M.H., Fegley D., Mangieri R., Krey J.F., Walker J.M., Holmes P.V., Crystal J.D., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. An endocannabinoid mechanism for stress-induced analgesia. Nature 435 (2005) 1108-1112
54. Howlett A.C., and Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem. Phys. Lipids 108 (2000) 53-70
55. Ilgen M.A., and Hutchison K.E. A history of major depressive disorder and the response to stress. J. Affect. Disord. 86 (2006) 143-150
56. Isbell H., Gorodetzsky C.W., Jasinski D., Claussen U., von Spulak F., and Korte F. Effects of (-)delta-9-tetrahydrocannabinol in man. Psychopharmacology 11 (1967) 184-188
57. Jaferi A., and Bhatnagar S. Corticosterone can act at the posterior paraventricular thalamus to inhibit hypothalamic-pituitary-adrenal activity in animals that habituate to repeated stress. Endocrinology 147 (2006) 4917-4930
58. Kamprath K., Marsicano G., Tang J., Monory K., Bisogno T., Di Marzo V., Lutz B., and Wotjak C.T. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J. Neurosci. 26 (2006) 6677-6686
59. Katona I., Urban G.M., Wallace M., Ledent C., Jung K.M., Piomelli D., Mackie K., and Freund T.F. Molecular composition of the endocannabinoid system at glutamatergic synapses. J. Neurosci. 26 (2006) 5628-5637
60. Korte S.M., Koolhaas J.M., Wingfield J.C., and McEwen B.S. The Darwinian concept of stress: benefits of allostasis and costs of allostatic load and the trade-offs in health and disease. Neurosci. Biobehav. Rev. 29 (2005) 3-38
61. Leung D., Saghatelian A., Simon G.M., and Cravatt B.F. Inactivation of N-acyl phosphatidylethanolamine phospholipase d reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45 (2006) 4720-4726
62. Lichtman A.H., Hawkins E.G., Griffin G., and Cravatt B.F. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J. Pharmacol. Exp. Ther. 302 (2002) 73-79
63. Ligresti A., Cascio M.G., and Di Marzo V. Endocannabinoid metabolic pathways and enzymes. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 615-623
64. Liu J., Wang L., Harvey-White J., Osei-Hyiaman D., Razdan R., Gong Q., Chan A.C., Zhou Z., Huang B.X., Kim H.Y., and Kunos G. A biosynthetic pathway for anandamide. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 13345-13350
65. Malcher-Lopes R., Di S., Marcheselli V.S., Weng F.J., Stuart C.T., Bazan N.G., and Tasker J.G. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J. Neurosci. 26 (2006) 6643-6650
66. Manzaneres J., Corchero J., and Fuentes J.A. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res. 839 (1999) 173-179
67. Matyas F., Urban G.M., Watanabe M., Mackie K., Zimmer A., Freund T.F., and Katona I. Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology 54 (2008) 95-107
68. Mar A., Spreekmeester E., and Rochford J. Antidepressants preferentially enhance habituation to novelty in the olfactory bulbectomized rat. Psychopharmacology 150 (2000) 52-60
69. Mar A., Spreekmeester E., and Rochford J. Fluoxetine-induced increases in open-field habituation in the olfactory bulbectomized rat depend on test aversiveness but not on anxiety. Pharmacol. Biochem. Behav. 73 (2002) 703-712
70. 1 receptor signaling in the dorsal hippocampus elicits an antidepressant-like response. Behav. Pharmacol. 18 (2007) 431-438
71. Melis M., Perra S., Muntoni A.L., Pillolla G., Lutz B., Marsicano G., Di Marzo V., Gessa G.L., and Pistis M. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J. Neurosci. 24 (2004) 10707-10715
72. Moldrich G., and Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 21 (2000) 1735-1742
73. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
74. Nakazi M., Bauer U., Nickel T., Kathmann M., and Schlicker E. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 361 (2000) 80-84
75. Ohno-Shosaku T., Maejima T., and Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29 (2001) 729-738
76. Parolaro D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci. 65 (1999) 637-644
77. Patel S., Carrier E.J., Ho W.S., Rademacher D.J., Cunningham S., Reddy D.S., Falck J.R., Cravatt B.F., and Hillard C.J. The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J. Lipid Res. 46 (2005) 342-349
78. Patel S., Roelke C.T., Rademacher D.J., Cullinan W.E., and Hillard C.J. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145 (2004) 5431-5438
79. Patel S., Roelke C.T., Rademacher D.J., and Hillard C.J. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur. J. Neurosci. 21 (2005) 1057-1069
80. 1 receptor function and POMC gene expression in the rat brain. Eur. Neuropsychopharmacol. 14 (2004) S318
81. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4 (2003) 873-884
82. Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J., Rosenstock, J., RIO-North America Study Group, 2006.
83. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., Nomikos G.G., Carter P., Bymaster F.P., Leese A.B., and Felder C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301 (2002) 1020-1024
84. Rademacher D.J., and Hillard C.J. Interactions between endocannabinoids and stress-decreased sensitivity to natural reward. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007) 633-641
85. Rademacher D.J., Meier S.E., Shi L., Ho W.S.V., Jarrahian A., and Hillard C.J. Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 54 (2008) 108-116
86. Ross R.A. Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol. 140 (2003) 790-801
87. Rubino T., Guidali C., Vigano D., Realini N., Valenti M., Massi P., and Parolaro D. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 54 (2008) 151-160
88. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J., Elebring T., Nilsson K., Drmota T., and Greasely P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152 (2007) 984-986
89. Schlicker E., and Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22 (2001) 565-572
90. Schulkin J., Gold P.W., and McEwen B.S. Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load. Psychoneuroendocrinology 23 (1998) 219-243
91. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., and Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215 (1995) 89-97
92. Sun Y., Alexander S.P., Kendall D.A., and Bennett A.J. Cannabinoids and PPARalpha signalling. Biochem. Soc. Trans. 34 (2006) 1095-1097
93. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., and Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1998) 393-411
94. Tsou K., Nogueron M.I., Muthian S., Sanudo-Pena M.C., Hillard C.J., Deutsch D.G., and Walker J.M. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci. Lett. 254 (1998) 137-140
95. Uchigashima M., Narushima M., Fukaya M., Katona I., Kano M., and Watanabe M. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J. Neurosci. 27 (2007) 3663-3676
96. Ueda N. Endocannabinoid hydrolases. Prostaglandins Other Lipid Mediat. 68-69 (2002) 521-534
97. Uriguen L., Perez-Rial S., Ledent C., Palomo T., and Manzaneres J. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46 (2004) 966-973
98. Valverde O., Aso E., Ozaita A., Valdizan E., Pazos A., and Maldonado R. Depressive-like phenotype in mice lacking cannabinoid CB1 receptors. Eur. Neuropsychopharmacol. 16 (2006) S302
99. van der Stelt M., and Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur. J. Pharmacol. 480 (2003) 133-150
100. van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S., and RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
101. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makryannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., and Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
102. Vaughan C.W., and Christie M.J. Retrograde signalling by endocannabinoids. Handbook Exp. Pharmacol. 168 (2005) 367-383
103. Wade M.R., Degroot A., and Nomikos G.G. Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents. Eur. J. Pharmacol. 551 (2006) 162-167
104. Willner P., Muscat R., and Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci. Biobehav. Rev. 16 (1992) 525-534
105. Wilson R.I., and Nicoll R.A. Endocannabinoid signaling in the brain. Science 296 (2002) 678-682